Importantly, an anti-PD-L1 blocking antibody significantly reversed the EV-mediated inhibition of CD8+ T-cell activation, suggesting a prognostic values PD-L1 + ve EVs in predicting the effectiveness of therapy detection, as well as a new strategy to enhance T-cell-mediated immunotherapy against SCLC cancers. Here, CD274 is linked to cancer.